The Role of Postoperative Radiotherapy and Prognostic Model in Primary Squamous Cell Carcinoma of Parotid Gland.
parotid gland
prognostic risk
radiotherapy
squamous cell carcinoma
surgery
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
10
2020
accepted:
23
12
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Primary squamous cell carcinoma of parotid gland (parotid SCC) is a high malignant histologic subtype of parotid cancers with aggressive clinical presentation. However, the clinical features and survival benefit of postoperative radiotherapy (PORT) for primary parotid SCC are not well known. A retrospective population-based study was performed to identify the role of PORT in parotid SCC patients diagnosed between 1975 and 2016 from SEER database. A prognostic risk model was established based on patient clinical features, including age, tumor stage, and node involvement status. Patients were stratified into high, intermediate, and low risk according to this model. The survival benefit of radiotherapy was compared in the whole cohort and different risk groups. Nine hundred thirty-one parotid SCC patients were extracted from SEER database, 634 (68.1%) in the RT group and 286 (30.7%) in the non-RT group. Overall, 503 (54.0%) deaths occurred, with a median follow-up of 84 months, the 5-year OS was 43.6% in the whole cohort, 47.7 This prognostic model can separate the patients with parotid squamous cell carcinoma into different risk. PORT significantly improved the OS of patients with intermediate risk, whereas high-risk group may need more intensive treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Primary squamous cell carcinoma of parotid gland (parotid SCC) is a high malignant histologic subtype of parotid cancers with aggressive clinical presentation. However, the clinical features and survival benefit of postoperative radiotherapy (PORT) for primary parotid SCC are not well known.
METHODS
METHODS
A retrospective population-based study was performed to identify the role of PORT in parotid SCC patients diagnosed between 1975 and 2016 from SEER database. A prognostic risk model was established based on patient clinical features, including age, tumor stage, and node involvement status. Patients were stratified into high, intermediate, and low risk according to this model. The survival benefit of radiotherapy was compared in the whole cohort and different risk groups.
RESULTS
RESULTS
Nine hundred thirty-one parotid SCC patients were extracted from SEER database, 634 (68.1%) in the RT group and 286 (30.7%) in the non-RT group. Overall, 503 (54.0%) deaths occurred, with a median follow-up of 84 months, the 5-year OS was 43.6% in the whole cohort, 47.7
CONCLUSION
CONCLUSIONS
This prognostic model can separate the patients with parotid squamous cell carcinoma into different risk. PORT significantly improved the OS of patients with intermediate risk, whereas high-risk group may need more intensive treatment strategies.
Identifiants
pubmed: 33659214
doi: 10.3389/fonc.2020.618564
pmc: PMC7919850
doi:
Types de publication
Journal Article
Langues
eng
Pagination
618564Informations de copyright
Copyright © 2021 Qiu, Yang, Sun, Zhou, Xu, Luo, Wang, He, Liu and Yi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiat Oncol J. 2019 Jun;37(2):143-148
pubmed: 31266294
Int J Oral Maxillofac Surg. 2017 Mar;46(3):343-349
pubmed: 27769738
Head Neck. 2006 Jul;28(7):626-32
pubmed: 16475198
Am J Otolaryngol. 2001 Nov-Dec;22(6):400-6
pubmed: 11713725
Ann Surg Oncol. 1999 Dec;6(8):768-70
pubmed: 10622505
J Community Support Oncol. 2016 Jan;14(1):29-36
pubmed: 26870840
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):189-95
pubmed: 22330990
Head Neck Surg. 1987 Mar-Apr;9(4):235-40
pubmed: 3667298
Arch Otolaryngol Head Neck Surg. 1990 Mar;116(3):290-3
pubmed: 2306346
Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):79-85
pubmed: 9054880
BMC Cancer. 2019 May 3;19(1):417
pubmed: 31053107
Cancer. 2005 Jun 15;103(12):2544-50
pubmed: 15880750
Arch Otolaryngol Head Neck Surg. 1992 Aug;118(8):798-801
pubmed: 1642829
Plast Reconstr Surg. 1987 Apr;79(4):550-4
pubmed: 3823246
BMC Cancer. 2019 Jul 31;19(1):752
pubmed: 31366378
J Oral Maxillofac Surg. 2015 Sep;73(9):1860-4
pubmed: 25865716
Am J Otolaryngol. 2018 Jan - Feb;39(1):65-70
pubmed: 29089142
Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1319-26
pubmed: 2115032
Laryngoscope. 2019 Apr;129(4):883-889
pubmed: 30151947
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7
pubmed: 17241753
Head Neck. 2017 Apr;39(4):E55-E60
pubmed: 28170130
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):988-94
pubmed: 17234357
Head Neck. 2015 Jan;37(1):1-7
pubmed: 24339135
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11
pubmed: 15629600
Cancer Manag Res. 2019 Jan 29;11:1081-1085
pubmed: 30774436
Cancer. 1980 Feb 15;45(4):693-7
pubmed: 6244072
Arch Otolaryngol. 1976 Jun;102(6):355-7
pubmed: 1275803
Br J Cancer. 1999 Jun;80(8):1296-300
pubmed: 10376987
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):112-8
pubmed: 15629601
Laryngoscope. 1990 Feb;100(2 Pt 1):146-8
pubmed: 2299955
Arch Otolaryngol. 1982 Nov;108(11):710-3
pubmed: 7138365
Am J Clin Oncol. 1986 Dec;9(6):510-6
pubmed: 3788853
Radiother Oncol. 2005 Nov;77(2):137-42
pubmed: 16260054